What is Leerink Partnrs’ Estimate for BBIO FY2028 Earnings?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Stock analysts at Leerink Partnrs decreased their FY2028 EPS estimates for BridgeBio Pharma in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of $4.31 per share for the year, down from their prior forecast of $4.38. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.59) per share.

BBIO has been the subject of a number of other research reports. Leerink Partners reduced their price objective on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Scotiabank assumed coverage on BridgeBio Pharma in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $44.00 price target on the stock. Oppenheimer assumed coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They set a “market perform” rating on the stock. Evercore ISI reduced their price target on BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, Bank of America reaffirmed a “buy” rating and set a $42.00 price target on shares of BridgeBio Pharma in a research report on Wednesday, September 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $47.50.

BridgeBio Pharma Stock Down 2.7 %

Shares of NASDAQ:BBIO opened at $24.11 on Thursday. The company has a market capitalization of $4.53 billion, a price-to-earnings ratio of -10.00 and a beta of 1.09. BridgeBio Pharma has a 52 week low of $21.62 and a 52 week high of $44.32. The firm has a 50 day moving average of $25.78 and a 200 day moving average of $26.44.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $25.75, for a total value of $149,350,000.00. Following the sale, the insider now directly owns 25,260,971 shares of the company’s stock, valued at approximately $650,470,003.25. This represents a 18.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Brian C. Stephenson sold 4,155 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $24.69, for a total transaction of $102,586.95. Following the completion of the sale, the chief financial officer now directly owns 85,192 shares in the company, valued at approximately $2,103,390.48. The trade was a 4.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,831,544 shares of company stock valued at $150,128,821 in the last ninety days. Company insiders own 24.66% of the company’s stock.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds have recently added to or reduced their stakes in the business. Erste Asset Management GmbH purchased a new stake in BridgeBio Pharma in the third quarter valued at $3,497,000. Rockefeller Capital Management L.P. boosted its stake in shares of BridgeBio Pharma by 11.7% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 41,259 shares of the company’s stock worth $1,050,000 after acquiring an additional 4,317 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of BridgeBio Pharma during the 3rd quarter worth about $383,000. Algert Global LLC boosted its stake in shares of BridgeBio Pharma by 144.3% during the 3rd quarter. Algert Global LLC now owns 136,447 shares of the company’s stock worth $3,474,000 after acquiring an additional 80,599 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of BridgeBio Pharma by 8.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,284,802 shares of the company’s stock worth $32,711,000 after acquiring an additional 95,605 shares in the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.